BIOMILQ

About BIOMILQ

BIOMILQ, a mammary biotechnology company, was established in Durham, North Carolina, in 2020. The company was co-founded by Michelle Egger, a food scientist, and Dr. Leila Strickland, a cell biologist. Dr. Strickland's journey into this venture was deeply personal, sparked by her own challenges with breastfeeding and inspired by the creation of the first lab-grown burger in 2013. This led her to explore using cell culture to produce milk outside the body. Michelle Egger brought her expertise from roles at General Mills and the Bill & Melinda Gates Foundation, where she focused on nutrition and social impact. The two were introduced by a mutual friend, uniting their shared passion for solving malnutrition through science.

The company's core business revolves around producing human milk components from cultured mammary cells in a lab setting. Using a patent-pending technology, BIOMILQ cultivates mammary epithelial cells in bioreactors that mimic the conditions inside the human body, stimulating the cells to secrete milk components. This process aims to create a product that is nutritionally closer to human breast milk than traditional bovine-based infant formula, providing a new supplemental feeding option for families. The target clients are parents who are unable to breastfeed or seek alternatives to infant formula for various reasons, including medical challenges, low milk production, or lifestyle choices. The business model appeared to be focused on a direct-to-consumer approach initially, with the potential for the product to be supplied as a liquid or a powder. The company's work was positioned to disrupt the multi-billion dollar infant formula market by offering a product with a lower environmental footprint compared to dairy-based formula.

BIOMILQ successfully produced the world's first cell-cultured human milk outside of the breast in June 2021, a significant milestone demonstrating that their product contained macronutrient profiles closely matching those in human milk, including proteins, complex carbohydrates, and bioactive lipids. The company secured substantial financial backing, raising a total of $24.5 million over two funding rounds. A seed round in June 2020 brought in $3.5 million, led by Breakthrough Energy Ventures, an investment firm founded by Bill Gates. This was followed by a $21 million Series A round in October 2021, co-led by Novo Holdings and Breakthrough Energy Ventures. However, the company later faced significant challenges. In January 2025, BIOMILQ filed for bankruptcy, citing that a protracted intellectual property dispute had rendered the firm "uninvestable and unacquirable." Prior to this, the company had pivoted from producing whole cultured milk to focusing on high-value bioactive components found in breastmilk.